Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Takeda Chairman Hasegawa to Retire, Become Adviser in June
Yasuchika Hasegawa, chairman of Takeda Pharmaceutical who has spearheaded the Japanese giant’s global expansions, bringing in non-Japanese executives including current CEO Christophe Weber, will step down and become the company’s adviser in June. Takeda said on April 13 that it…
To read the full story
Related Article
- Former Takeda CEO Yasuchika Hasegawa Dies at 80
September 11, 2026
- Takeda Chairman Hasegawa Officially Steps Aside as Adviser
June 29, 2017
BUSINESS
- Gilead Paints Sustained Growth Curve with Trodelvy, CAR-T Therapies
October 2, 2026
- Novo Expands Oral Obesity Arsenal, Hengrui Asset Eyed around 2030
October 1, 2026
- Bayer Takes Dialogue-Driven Innovation Model Nationwide
October 1, 2026
- Chugai to Set Up South Korea Unit, Take Sales In-House
October 1, 2026
- Daito Reveals Meiji, DBJ as Partners in Kyorin Generics JV
October 1, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…